Several other research analysts also recently commented on IONS. Cantor Fitzgerald decreased their price objective on Ionis Pharmaceuticals from $65.00 to $56.00 and set a neutral rating on the stock in a report on Thursday, March 26th. Zacks Investment Research downgraded Ionis Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, May 13th. JPMorgan Chase & Co. lifted their price objective on Ionis Pharmaceuticals from $58.00 to $60.00 and gave the stock a neutral rating in a report on Monday, March 9th. Citigroup lifted their price objective on Ionis Pharmaceuticals from $71.00 to $80.00 and gave the stock a buy rating in a report on Friday, June 5th. Finally, ValuEngine downgraded Ionis Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, April 30th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. Ionis Pharmaceuticals has an average rating of Hold and a consensus price target of $73.13.
Shares of IONS stock opened at $58.96 on Friday. The company has a quick ratio of 9.83, a current ratio of 9.91 and a debt-to-equity ratio of 0.51. The business has a 50-day moving average price of $56.72 and a two-hundred day moving average price of $56.41. Ionis Pharmaceuticals has a 12-month low of $39.32 and a 12-month high of $73.09. The firm has a market cap of $8.18 billion, a P/E ratio of 53.60 and a beta of 1.68.
In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 15,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $57.90, for a total transaction of $868,500.00. Following the sale, the chairman now directly owns 26,935 shares of the company’s stock, valued at approximately $1,559,536.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Stanley T. Crooke sold 5,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $58.80, for a total value of $294,000.00. Following the sale, the chairman now directly owns 11,935 shares in the company, valued at $701,778. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 70,000 shares of company stock worth $4,123,750. Insiders own 2.67% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of IONS. Americana Partners LLC bought a new stake in shares of Ionis Pharmaceuticals in the 4th quarter worth approximately $29,000. Balentine LLC bought a new position in Ionis Pharmaceuticals in the 1st quarter valued at approximately $29,000. Cornerstone Advisors Inc. lifted its position in Ionis Pharmaceuticals by 107.2% in the 1st quarter. Cornerstone Advisors Inc. now owns 663 shares of the company’s stock valued at $31,000 after acquiring an additional 343 shares in the last quarter. Chevy Chase Trust Holdings Inc. bought a new position in Ionis Pharmaceuticals in the 4th quarter valued at approximately $37,000. Finally, NWK Group Inc. bought a new position in Ionis Pharmaceuticals in the 4th quarter valued at approximately $39,000. 84.02% of the stock is currently owned by hedge funds and other institutional investors.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Read More: Forex
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.